Test Strip Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Test Strip Market Report is Segmented by Product (Blood Test Strips and Urine Test Strips), Application (Diabetes, Pregnancy Detection, Urinary Tract Infection, and More), End User (Hospitals & Clinics, Homecare / Personal Use, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More), and Geography (North America, Europe and More). The Market Forecasts are Provided in Terms of Value (USD).

Test Strip Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Test Strip Market with other markets in Healthcare Industry

Test Strip Market Analysis by Mordor Intelligence

The Test Strip Market size is estimated at USD 16.69 billion in 2025, and is expected to reach USD 20.18 billion by 2030, at a CAGR of 3.87% during the forecast period (2025-2030). The trajectory reflects a sector balancing the gradual contraction of glucose-only demand against rising sales in multi-analyte, preventive, and home-based diagnostics. Blood glucose strips still represent the largest revenue pool, yet the swift uptake of urine panels, ketone checks, and pregnancy assays signals broader clinical utility. Regionally, North America anchors current revenue while Asia-Pacific supplies incremental volume growth, powered by rising diabetes prevalence and digital health adoption. Competitive intensity remains moderate as established brands respond to continuous glucose monitoring (CGM) cannibalization with technology upgrades and bundled digital ecosystems. Strategic risk centers on enzyme-coated substrate supply chains, although recombinant alternatives promise cost and quality gains.

Key Report Takeaways

  • By product, blood strips led with 71.34% revenue share in 2024, while urine strips are projected to advance at a 5.13% CAGR to 2030.  
  • By application, diabetes maintained 65.85% share of the test strip market size in 2024, whereas urinary tract infection screening is expanding at a 4.64% CAGR through 2030.  
  • By end user, the homecare segment captured 49.34% of the test strip market share in 2024 and is progressing at a 4.12% CAGR.  
  • By distribution channel, retail pharmacies held 61.13% of the test strip market size in 2024; online pharmacies register the fastest growth at 4.93% CAGR.  
  • North America dominated with 38.18% revenue share in 2024, yet Asia-Pacific will record the highest regional CAGR at 5.34% through 2030.  

Segment Analysis

By Product: Blood Strips Dominate Despite Urine Growth

Blood glucose strips generated 71.34% of 2024 revenue for the test strip market, anchored by entrenched therapeutic guidelines and insurance coverage. The segment benefits from enzymatic refinements that enable 0.5 microliter samples and 7-second reads, showcased by ARKRAY’s GLUCOCARD Vital platform. Yet, urine panels are expanding at a 5.13% CAGR as healthcare providers promote early screening for urinary tract infections, kidney disease, and pregnancy. ARKRAY’s 11-parameter AUTION line illustrates the multi-analyte advantage, encouraging physicians to replace single-purpose strips with comprehensive urinalysis.

Growth momentum in urine diagnostics hinges on preventive medicine trends. Digital telehealth platforms in urban China integrate home urine strips with cloud analytics, enabling remote physician oversight and medication adherence tracking. Blood-strip makers counter by embedding Bluetooth and EHR connectivity to preserve relevance. 

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Application: Diabetes Leadership Faces UTI Challenge

Diabetes care produced 65.85% of 2024 revenue for the test strip market, yet its growth is moderating to 3.1% annually as CGM substitution accelerates in high-income markets. Conversely, urinary tract infection screening is accelerating at 4.64% CAGR, supported by primary-care protocols that favor rapid POC urinalysis to curb antibiotic misuse. Pregnancy testing maintains steady demand, aided by dual fertility functions and smartphone readers that improve result interpretation.

Clinical guidelines recommending quarterly HbA1c POC tests extend strip-based HbA1c opportunities in both urban and rural China, where cost-utility ratios fall well below local GDP per capita thresholds. The test strip industry also witnesses crossover innovation. Researchers adapted glucometers to quantify SARS-CoV-2 antibodies, proving the platform’s flexibility for future multiplex infectious disease panels.

By End User: Homecare Dominance Reflects Patient Empowerment

Home users accounted for 49.34% of revenue in 2024 and will continue outpacing institutional channels. Simplified sample handling, automated lancet-strip combinations, and mobile dashboards give consumers real-time decision support. Medicare’s mail-order program further cements home supply continuity. POGO Automatic’s integrated cartridge system exemplifies friction-free operation, drawing adoption among tech-savvy younger cohorts.

Hospitals and clinics remain vital for complex case management and perioperative monitoring. BD’s MiniDraw fingertip device delivers venous-equivalent results, strengthening the case for strip-based assays in acute settings. Diagnostic laboratories leverage high-throughput auto-readers for chronic disease panels, yet their share erodes as payers favor decentralized care models.

Test Strip Market: Market Share by End User
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Retail Pharmacy Strength Meets Online Growth

Retail pharmacies held 61.13% of the test strip market in 2024 due to immediate availability and pharmacist counseling. Loyalty programs and Medicare copay handling preserve foot traffic. Online pharmacies, however, are scaling 4.93% annually through subscription refills, predictive shipping algorithms, and lower overhead costs. Direct-to-consumer models provide manufacturers with margin gains and data insights that inform future device design.

Regulatory continuity assists both channels. The FDA’s Laboratory Developed Test rule creates unified quality expectations and stabilizes distribution planning through a four-year phase-in. Retailers and e-commerce operators alike align with emerging Unique Device Identifier requirements, facilitating recalls and counterfeit mitigation.

Geography Analysis

North America generated 38.18% of 2024 revenue for the test strip market, enabled by well-established insurance coverage and widespread chronic disease management programs. Medicare’s 300-strip quarterly limit for insulin users ensures baseline demand, and the 2024 USD 35 insulin copay cap frees consumer cash for ancillary supplies. Yet, CGM expansion moderates volume growth as Abbott and Medtronic push OTC sensors to retail shelves. Federal Laboratory Developed Test policy changes introduce predictable compliance pathways, encouraging multinational entrants to sustain investment.

Asia-Pacific delivers the fastest regional CAGR at 5.34%, driven by climbing diabetes prevalence, urban dietary shifts, and expanding middle-class purchasing power. China’s integrated digital management initiatives cut average fasting glucose by 1.68 mmol/L in Tianjin pilots, underscoring demand for connected home testing. India’s domestic manufacturing scale-up from 2.5 million to 5 million glucometers annually lifts supply resilience, while lower per-capita income keeps price elasticity high. Point-of-care HbA1c screening in rural China also proves cost-effective, demonstrating the appeal of compact strip readers in resource-constrained settings.

Europe sustains moderate expansion under the In Vitro Diagnostic Regulation transitional timelines to 2027-2029, which maintain device availability during recertification. Partnership-led growth emerges as A. Menarini secures exclusive Sinocare CGM rights across more than 20 jurisdictions, blending continuous and strip-based portfolios. Meanwhile, Middle East, Africa, and South America represent nascent demand pools where limited reimbursement favors low-priced strips over premium CGM hardware.

Test Strip Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Competition in the test strip market shows moderate fragmentation. Abbott, Roche, and LifeScan control leading channel relationships and invest in integrated ecosystems to offset CGM substitution. Abbott’s Libre data feed into Epic electronic records locks in provider loyalty, while Roche released an AI-enabled CGM predictive tool to keep engagement high. LifeScan leverages OneTouch Reveal cloud analytics to maintain relevance despite shrinking strip volumes.

Mid-tier players differentiate through multi-parameter innovation. ARKRAY pairs blood and urine lines with temperature correction features that boost accuracy across climate zones. Siemens Healthineers integrates strip autoloaders into lab informatics suites, bridging point-of-care and core-lab workflows. Regional specialists such as Sinocare scale cost-advantaged production for emerging markets, while Morepen Labs expands domestically to meet Indian demand peaks.

Supply chain strategy is an emerging competitive metric. Vienna University of Technology’s E.coli-derived horseradish peroxidase opens licensing opportunities to reduce agriculture risk. Companies securing such bioprocessing know-how gain margin and risk advantages. Strategic moves also include portfolio rationalization: Asahi Kasei divested certain diagnostics lines to concentrate on high-growth segments. Partnerships, such as Abbott–Medtronic data-sharing agreements, highlight a broader shift toward ecosystem interoperability that blurs company boundaries.

Test Strip Industry Leaders

  1. ARKRAY, Inc.

  2. Ascensia Diabetes Care Holdings AG

  3. Abbott

  4. F. Hoffmann-La Roche

  5. LifeScan

  6. *Disclaimer: Major Players sorted in no particular order
Test Strip Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • November 2024: Beurer India launched the GL 22 Blood Glucose Monitor along with companion strips.
  • October 2024: Trividia Health TRUE METRIX strip line gained preferred status across all Florida Managed Medicaid plans.
  • June 2024: Researchers at India’s National Institute of Technology Raipur created a urine-based glucose strip that may remove finger-prick barriers.
  • April 2024: OVUM launched the nation's first fully recyclable early-detection pregnancy tests. Its products are sold in Sainsbury's stores across the United Kingdom. OVUM's B Corp certification highlights its commitment to environmental and social responsibility. This focus on sustainability, alongside its innovative products, is expected to resonate with eco-conscious consumers.

Table of Contents for Test Strip Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Surging Global Diabetes Prevalence
    • 4.2.2 Preference Shift to Point-Of-Care Diagnostics
    • 4.2.3 Continuous Technology Upgrades in Enzymatic Chemistries
    • 4.2.4 Smartphone-Enabled Optical Strip Readers Gain Regulatory Green-Lights
    • 4.2.5 Expanded Applications - UTIs, Pregnancy, etc.
    • 4.2.6 Supportive Healthcare Policies and Awareness
  • 4.3 Market Restraints
    • 4.3.1 Sparse Reimbursement for OTC Strip Purchases
    • 4.3.2 Accuracy Concerns Versus Lab-Based Reference Tests
    • 4.3.3 Enzyme-Coated Substrate Supply Volatility
    • 4.3.4 CGM Uptake Cannibalising Glucose-Strip Volumes
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook
  • 4.6 Porter’s Five Forces Analysis
    • 4.6.1 Threat of New Entrants
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Bargaining Power of Suppliers
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Product
    • 5.1.1 Blood Test Strips
    • 5.1.2 Urine Test Strips
  • 5.2 By Application
    • 5.2.1 Diabetes
    • 5.2.2 Pregnancy Detection
    • 5.2.3 Urinary Tract Infection
    • 5.2.4 Other Applications
  • 5.3 By End User
    • 5.3.1 Hospitals & Clinics
    • 5.3.2 Homecare / Personal Use
    • 5.3.3 Diagnostic Laboratories
  • 5.4 By Distribution Channel
    • 5.4.1 Hospital Pharmacies
    • 5.4.2 Retail Pharmacies
    • 5.4.3 Online Pharmacies
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Abbott
    • 6.3.2 ACON Laboratories
    • 6.3.3 Ascensia Diabetes Care
    • 6.3.4 ARKRAY, Inc.
    • 6.3.5 B. Braun SE
    • 6.3.6 LifeScan
    • 6.3.7 F. Hoffmann-La Roche
    • 6.3.8 Siemens Healthineers
    • 6.3.9 TaiDoc
    • 6.3.10 Trividia Health
    • 6.3.11 Nova Biomedical
    • 6.3.12 Danaher (Beckman Coulter)
    • 6.3.13 Medtronic
    • 6.3.14 Becton Dickinson
    • 6.3.15 OraSure Technologies
    • 6.3.16 QuidelOrtho
    • 6.3.17 CoaguSense

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Test Strip Market Report Scope

As per the scope of the report, a test strip is a key component of blood glucose testing and urinalysis. It is used to monitor or control a diabetic patient's blood glucose level. It allows people who are pre-diabetic or diabetic to monitor their blood glucose levels regularly without going to a clinic or a diagnostic laboratory.

The test strip market is segmented by product (blood test strips and urine test strips), application (diabetes, pregnancy, urinary tract infection, and other applications), end user (hospitals, home care, and diagnostic laboratories), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market sizes and forecasts in terms of value (USD) for the above-mentioned segments.

By Product Blood Test Strips
Urine Test Strips
By Application Diabetes
Pregnancy Detection
Urinary Tract Infection
Other Applications
By End User Hospitals & Clinics
Homecare / Personal Use
Diagnostic Laboratories
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product
Blood Test Strips
Urine Test Strips
By Application
Diabetes
Pregnancy Detection
Urinary Tract Infection
Other Applications
By End User
Hospitals & Clinics
Homecare / Personal Use
Diagnostic Laboratories
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the projected value of the test strip market in 2030?

The test strip market is forecast to reach USD 20.18 billion by 2030 based on a 3.87% CAGR.

Which product segment is growing fastest?

Urine test strips are the fastest-growing segment, expanding at a 5.13% CAGR as healthcare shifts toward preventive screening.

How is CGM adoption affecting traditional strip demand?

In developed markets, CGM users cut daily strip use nearly in half, leading to a −0.9% impact on overall CAGR despite rising diabetes incidence.

Which region will contribute most to incremental growth?

Asia-Pacific will supply the largest share of new volume, with a 5.34% regional CAGR driven by rising prevalence and digital health programs.

What role do retail pharmacies play in distribution?

Retail pharmacies account for 61.13% of 2024 revenue, but online channels are growing faster at 4.93% CAGR due to subscription refill models.

Page last updated on: June 30, 2025

Test Strip Market Report Snapshots